olfactory receptor family 7 subfamily E member 94 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR7E94P profile across patient tissues and cancer cell-line models. OR7E94P expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, OR7E94P is differentially expressed in 12, with the highest sampling consensus in BLCA. Additionally, OR7E94P RNA expression shows 9,491 significant protein co-abundance associations, with the highest sampling consensus in CCRCC. Together, these results highlight HNSC, BLCA, and CCRCC as cancer lineages where OR7E94P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR7E94P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR7E94P survival associations across molecular data types. OR7E94P RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR7E94P RNA expression–survival associations across cancer types. High OR7E94P expression shows unfavorable associations in LAML, but favorable associations in HNSC, SKCM, CESC, KIRC and CHOL. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for OR7E94P RNA expression.
This table summarizes OR7E94P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR7E94P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR7E94P shows lower tumor expression in BLCA, LUSC, LUAD, COAD and BRCA and higher tumor expression in KIRC. The BLCA box plot shows higher OR7E94P RNA expression in normal versus tumor tissue (log2 FC = −0.192, t-test p < 0.001).
This table shows molecular features associated with OR7E94P in patient tissues and cancer cell lines. In patient samples, OR7E94P shows the broadest associations at the RNA and protein expression levels, with CCRCC recurring as the lineage with the largest associated feature set.
